Denali Therapeutics, Inc. (DNLI)
20.00
-0.53
(-2.58%)
USD |
NASDAQ |
Oct 02, 16:00
20.02
+0.02
(+0.10%)
After-Hours: 20:00
Denali Therapeutics Enterprise Value : 2.522B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 2.522B |
| October 01, 2026 | 2.607B |
| September 30, 2026 | 2.629B |
| September 29, 2026 | 2.652B |
| September 28, 2026 | 2.679B |
| September 25, 2026 | 2.585B |
| September 24, 2026 | 2.597B |
| September 23, 2026 | 2.596B |
| September 22, 2026 | 2.778B |
| September 21, 2026 | 2.597B |
| September 18, 2026 | 2.478B |
| September 17, 2026 | 2.543B |
| September 16, 2026 | 2.532B |
| September 15, 2026 | 2.583B |
| September 14, 2026 | 2.717B |
| September 11, 2026 | 2.696B |
| September 10, 2026 | 2.746B |
| September 09, 2026 | 2.773B |
| September 08, 2026 | 2.855B |
| September 04, 2026 | 2.887B |
| September 03, 2026 | 2.970B |
| September 02, 2026 | 2.978B |
| September 01, 2026 | 3.044B |
| August 31, 2026 | 3.123B |
| August 28, 2026 | 3.161B |
| Date | Value |
|---|---|
| August 27, 2026 | 3.268B |
| August 26, 2026 | 3.252B |
| August 25, 2026 | 3.310B |
| August 24, 2026 | 3.193B |
| August 21, 2026 | 3.308B |
| August 20, 2026 | 3.313B |
| August 19, 2026 | 3.431B |
| August 18, 2026 | 3.211B |
| August 17, 2026 | 3.217B |
| August 14, 2026 | 3.225B |
| August 13, 2026 | 3.292B |
| August 12, 2026 | 3.364B |
| August 11, 2026 | 3.272B |
| August 10, 2026 | 3.321B |
| August 07, 2026 | 3.294B |
| August 06, 2026 | 3.278B |
| August 05, 2026 | 3.228B |
| August 04, 2026 | 3.189B |
| August 03, 2026 | 3.026B |
| July 31, 2026 | 3.005B |
| July 30, 2026 | 3.217B |
| July 29, 2026 | 3.137B |
| July 28, 2026 | 3.169B |
| July 27, 2026 | 3.093B |
| July 24, 2026 | 3.019B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 8.834B |
| Oncolytics Biotech, Inc. | 74.98M |
| Sangamo Therapeutics, Inc. | 52.85M |
| Sarepta Therapeutics, Inc. | 2.106B |
| Anixa Biosciences, Inc. | 87.06M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -127.55M |
| Revenue (Quarterly) | 3.604M |
| Total Expenses (Quarterly) | 131.16M |
| EPS Diluted (Quarterly) | -0.681 |
| Gross Profit Margin (Quarterly) | -52.39% |
| Profit Margin (Quarterly) | -3.54K% |
| Earnings Yield | -14.19% |
| Normalized Earnings Yield | -14.19 |